Episodes 61-75 of 253
Safety and Efficacy of Onasemnogene Abeparvovec in Pediatric SMA Across Expanded Weight Cohorts
NeuroFrontiersSafety and Efficacy of Onasemnogene Abeparvovec in Pediatric SMA Across Expanded Weight Cohorts
New-Onset Ketosis-Prone Diabetes in an Adult with Spinal Muscular Atrophy Type III
NeuroFrontiersNew-Onset Ketosis-Prone Diabetes in an Adult with Spinal Muscular Atrophy Type III
Reevaluating Spinal Muscular Atrophy Therapy: Signs, Tools, and Strategies
NeuroFrontiersReevaluating Spinal Muscular Atrophy Therapy: Signs, Tools, and Strategies
Closing Care Gaps and Addressing Unmet Needs in SMA
NeuroFrontiersClosing Care Gaps and Addressing Unmet Needs in SMA
Examining Care Collaborations for Patients with SMA
NeuroFrontiersExamining Care Collaborations for Patients with SMA
- advertisement
Timely ATTR-CM Diagnosis: Addressing Social Determinants of Health
Heart MattersTimely ATTR-CM Diagnosis: Addressing Social Determinants of Health
Equitable Care for ATTR-CM: Improving Early Diagnosis in High-Risk Groups
Heart MattersEquitable Care for ATTR-CM: Improving Early Diagnosis in High-Risk Groups
Assessing Adverse Pregnancy Outcomes in Isolated Sjögren’s Disease
Living RheumAssessing Adverse Pregnancy Outcomes in Isolated Sjögren’s Disease
From Infusion Chair to Clinic Visit: How Subcutaneous Nivolumab May Simplify RCC Care
Project Oncology®From Infusion Chair to Clinic Visit: How Subcutaneous Nivolumab May Simplify RCC Care
Reframing Sjögren’s Syndrome: Insights from a Comprehensive Review
Living RheumReframing Sjögren’s Syndrome: Insights from a Comprehensive Review
Efgartigimod Shows Early Promise for Primary Sjögren’s Disease
Living RheumEfgartigimod Shows Early Promise for Primary Sjögren’s Disease
- advertisement
Unmasking Patient Subtypes in Sjögren’s Disease to Enable Personalized Care
Living RheumUnmasking Patient Subtypes in Sjögren’s Disease to Enable Personalized Care
Translating Patisiran’s 6-Minute Walk Test Gains into Real-Life Impact in ATTR-CM
Heart MattersTranslating Patisiran’s 6-Minute Walk Test Gains into Real-Life Impact in ATTR-CM
Staging the Benefit: Tafamidis Outcomes in ATTR-CM Depend on Timing
Heart MattersStaging the Benefit: Tafamidis Outcomes in ATTR-CM Depend on Timing
